ABSTRACT
A 12-week, double-blind, placebo-controlled, multicenter study evaluated the efficacy and safety of flexible-dose sildenafil citrate (Viagra) treatment (25, 50 or 100 mg) in Brazilian and Mexican men with erectile dysfunction (ED) of broad-spectrum etiology. Efficacy was assessed on the basis of responses to the 15-item International Index of Erectile Function (IIEF) questionnaire, completed at baseline and after 12 weeks of treatment. At end point, mean scores for all IIEF domains of sexual function (erectile function, orgasmic function, sexual desire, intercourse satisfaction and overall satisfaction) were significantly (P<0.0001) higher in the sildenafil group (n=109) than in the placebo group (n=105). These findings confirm the significant increases in frequency of penetration and frequency of maintained erections reported previously. Sildenafil treatment was well tolerated. The most common adverse events were headache and flushing. In conclusion, sildenafil is a well-tolerated and effective treatment for ED of broad-spectrum etiology in Latin American men.
Subject(s)
Erectile Dysfunction/drug therapy , Piperazines/administration & dosage , Vasodilator Agents/administration & dosage , Administration, Oral , Adult , Aged , Aged, 80 and over , Brazil , Dose-Response Relationship, Drug , Double-Blind Method , Humans , Libido/drug effects , Male , Mexico , Middle Aged , Orgasm/drug effects , Patient Satisfaction , Piperazines/adverse effects , Piperazines/therapeutic use , Purines , Safety , Sildenafil Citrate , Sulfones , Treatment Outcome , Vasodilator Agents/adverse effects , Vasodilator Agents/therapeutic useABSTRACT
Se valoró, mediante estudio clínico multicéntrico, prospectivo y abierto, la eficacia, seguridad y aceptación de cinoxacino, en dosis de 250 mg cada doce horas, durante 10 días, para el tratamiento de infección aguda no complicada ni recurrente del aparato urinario, por bacterias sensibles al medicamento. La respuesta clínica y bacteriológica fue satisfactoria en todos los casos estudiados que se apegaron al protocolo de estudio. Se obtuvo respuesta clínica satisfactoria en 92% de 37 pacientes estudiados y respuesta bacteriológica favorable (eliminación del patógeno aislado antes del inicio del estudio) en 88%. No se observó toxicidad por la administración del medicamento y los efectos indeseables fueron de intensidad y duración moderadas que en ningún caso ameritaron suspensión del medicamento
